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Abstract — Aims: Various studies have shown that plasma homocysteine (HCY) serum levels are elevated in actively drinking
alcohol-dependent patients a during alcohol withdrawal, while rapidly declining during abstinence. Hyperhomocysteinemia has been
associated not only with blood alcohol concentration (BAC), but also with deficiency of different B-vitamins, particularly folate,
pyridoxine and cobalamin. Methods: Our study included 168 inpatients (110 men, 58 women) after admission for detoxification
treatment. BAC, folate, cobalamin, pyridoxine, thiamine and riboflavin were obtained on admission (Day 1). HCY was assessed on
Days 1, 7 and 11. Results: HCY levels significantly declined during withdrawal. General linear models and linear regression analysis
showed an influence of BAC, folate and riboflavin on the HCY levels on admission as well as on HCY changes occurring during
alcohol withdrawal. No significant influence was found for thiamine, cobalamin and pyridoxine. Conclusions: These findings show
that not only BAC and plasma folate levels, but also plasma levels of riboflavin influence HCY plasma levels in alcohol-dependent
patients.
INTRODUCTION
Homocysteine (HCY) metabolism is known to be fundamen-
tally altered during alcohol intoxication and withdrawal
(Bleich et al., 2000b, 2004, 2005). This has been shown for
alcohol-dependent patients, but also—to a lesser extent—for
social drinkers (Bleich et al., 2001). HCY levels found in
alcohol-dependent patients tend to be much higher than the
common cut-off levels for HCY, defined in a study of
Ubbink et al. (1995) as 11.7 μmol/l or in a different investi-
gation as 11.4 μmol/l for male and 10.4 μmol/l for female
subjects (Selhub et al., 1999).
The amino acid HCY is known to increase glutamatergic
neurotransmission via activation of the N-methyl-D-aspartate
(NMDA)-receptor of the glutamatergic system (Bleich et al.,
2004; Bleich and Hillemacher, 2009). Elevated HCY levels
lead to neurodegeneration and have been associated—inter
alia—with vascular diseases and brain atrophy (Sachdev,
2004; Wilhelm et al., 2008). During alcohol withdrawal
neurotransmission via the (up-regulated) NMDA-receptors is
not longer blocked by ethanol, resulting in an extensive over-
stimulation by HCY-associated NMDA-receptor agonism.
This extensive glutamatergic reaction has been assumed to be
the neurobiological background of the association between
elevated HCY levels and the higher risk of alcohol withdraw-
al seizures (Bleich et al., 2000a, 2006; Bayerlein et al., 2005;
Hillemacher et al., 2007). Furthermore, elevated HCY levels
have been found to correlate with short-term cognition defi-
cits during alcohol withdrawal (Wilhelm et al., 2006) as well
as long-term cerebral atrophy (Bleich et al., 2003).
This increase in HCY levels in alcohol-dependent patients
is based on the direct effects of ethanol (Bleich et al., 2000b,
2005) as well as an alcohol-associated deficiency of folate
(vitamin B9), cobalamin (vitamin B12) and pyridoxine
(vitamin B6) (Majumdar et al., 1982; Cravo and Camilo,
2000; Bleich et al., 2004; Chen et al., 2011). Folate and 5-
methyltetrahydrofolate are substrates for the remethylation of
HCY to methionine via the action of the methionine synthase
(Moat et al., 2003; Bleich et al., 2004), cobalamin acts as a
cofactor for methionine synthase. Riboflavin is a precursor
of flavin adenine dinucleotide (FAD), which is a coenzyme
of methylenetetrahydrofolate reductase (MTHFR) (Moat
et al., 2003). Pyridoxine acts as a cofactor for
cystathionine-β-synthase (CBS), responsible for transsul-
phuration of HCY into cystathionine (Bleich et al., 2004).
Thiamine has been supposed to act on the HCY metabolism
via enhancing the oxidative decarboxylation in the trans-
amination of methionine (Franken et al., 1996). The rele-
vance of B-vitamine intake on HCY levels has been shown
in numerous studies (Konstantinova et al., 2007).
The present study was performed to validate previous find-
ings investigating alterations of HCY serum levels during
alcohol withdrawal in a large population of alcohol-
dependent patients and to study the role of the B-vitamins
involved in HCY metabolism in the pathogenesis of
alcohol-associated hyperhomocysteinemia.
SUBJECTS AND METHODS
The present study was part of the German Investigation on
Neurobiology in Alcoholism (GINA). All patients were
recruited from the Department of Addiction and
Psychotherapy of the hospital ‘Rheinische Kliniken’ in
Bonn, Germany. Written informed consent was obtained
from all 363 patients (251 men, 112 women). In a subsample
of serial patients, we performed a prospective approach,
obtaining data on Days 1, Day 7 and Day 11 after admission
for detoxification treatment. This subsample was used in the
present analysis, consisting of 168 patients (110 men, 58
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women). All procedures were approved by the local ethics
committee of the University of Bonn, Germany (Nr. 024/07),
and were in accordance with the Helsinki Declaration of
1975, as revised in 1983. All participants suffered from
alcohol dependency according to ICD-10 and were included
in the study on admission for alcohol detoxification. Patients
were mainly detoxified using clomethiazole following a
symptom-triggered regime using the Banger-Score (Banger
et al., 1992). If, for clinical reasons, clomethiazole could not
be used, benzodiazepines were administered. Patients suffer-
ing from dependence of other substances except alcohol and
nicotine were excluded from the study.
Laboratory measurements
Fasting blood samples were obtained on Day 1 (admission),
7 and 11 of detoxification treatment. Blood samples were
centrifuged and consecutive serum and lithium heparin
plasma samples were stored at −80°C directly after collec-
tion. HCY was assessed at all three time points while
vitamin serum levels were obtained at admission.
Plasma total HCY concentrations were measured by means
of particle-enhanced immunonephelometry with a Dimension
Vista™ system according to the manufacturer’s instructions
(Siemens Healthcare Diagnostics, Eschborn, Germany). The
reference interval given by Siemens Healthcare Diagnostics
was 4.9–15.0 µmol/l. Serum vitamin B12 and folate concen-
trations were measured by means of a homogenous, competi-
tive chemiluminescent immunoassay based on the LOCI™
technology with a Dimension Vista™ system (Siemens
Healthcare Diagnostics). Reference intervals given by
Siemens Healthcare Diagnostics were 3.1–17.5 ng/ml for
folate and 254–1320 pg/ml for cobalamin.
Serum alcohol concentration was measured by means of an
enzymatic test (alcohol dehydrogenase method) with a
Dimension Vista™ system (Siemens Healthcare Diagnostics).
Blood concentrations of thiamine, riboflavin and pyridox-
ine were analyzed using commercially available high-per-
formance liquid chromatography (HPLC) assays
(Chromsystems Instruments & Chemicals GmbH, Munich,
Germany) on an HPLC system with a fluorescence detector
(Agilent, Series 1200, Agilent, Waldbronn, Germany).
Reference intervals given by Chromsystems were 66.5–200
nnmol/l for thiamine, 174–471 nmol/l for riboflavin and 8.7–
27.3 µg/l for pyridoxine.
Statistical assessment
Results are presented as mean + SD or SE. Variables were
normally distributed as tested using the Kolmogorov–
Smirnov test. Linear regression models and general linear
models for repeat measurements were used to test the influ-
ence of different variables on HCY levels. Significance level
(P-value) was set <0.05.
Data were analyzed using IBM SPSS Statistics 19.0 and
Graph Pad PrismTM 5.0 (Graph Pad Software Inc., San
Diego, CA, USA).
RESULTS
Demographic characteristics of the study population are
given in Table 1. Very few patients suffered from a definitive
B-vitamin deficiency (two patient presented folate defi-
ciency, one patient thiamine deficiency, yet none of the other
included B-vitamins).
Pearson’s correlation analysis showed significant results
for HCY and folate (r = −0.48, P < 0.001), HCY and ribofla-
vin (r = −0.28, P < 0.001) as well as for HCY and cobalamin
(r = −0.21, P = 0.005). HCY and thiamine as well as HCY
and pyridoxine were not significantly correlated.
Statistical analysis using general linear models for repeat
measurements showed that HCY levels decline rapidly during
alcohol withdrawal (F = 45.28, P < 0.001), with significant
differences between all time points (Day 1/7: P < 0.001; Day
1/11: P < 0.001; Day 7/11: P < 0.001; Fig. 1). A multivariate
linear regression model showed that HCY serum levels on
Day 1 of alcohol withdrawal are significantly influenced by
blood alcohol concentration (BAC) on admission (B = 1.60,
Table 1. Demographic characteristics of the study population
Mean SD Median Range
Age (years) 48.1 8.7 48.0 21–66
BAC (per mille) 1.46 1.1 1.43 0–4.2
HCY Day 1 (μmol/l) 19.6 12.9 15.3 5.5–94.9
HCY Day 7 (μmol/l) 12.9 5.9 11.6 5.1–55.9
HCY Day 11 (μmol/l) 11.9 5.1 10.7 0.2–50.4
Folate (ng/ml) 9.8 5.7 9.1 1.5–20.0
Riboflavin (nmol/l) 295.1 51.0 288.6 192.7–480.1
Thiamine (nmol/l) 164.4 47.1 160.9 16.8–338.6
Pyridoxine (μg/l) 31.4 48.9 25.1 10.6–522.6
Cobalamin (pg/ml) 705.7 293.8 650.0 228.0–1500.0
Sex male: n = 110 female: n = 58
Nicotine consumption
(males: n = 87)
24.1 10.2 20.0 5–60
Nicotine consumption
(females: n = 42)
21.7 9.2 20.0 6–40
SD, standard deviation; BAC, blood alcohol concentration at admission;
HCY, homocysteine serum levels, measured at Day 1, 7 or 11 after
admission for in-patients detoxification treatment.
Vitamin levels were measured at admission. Nicotine consumption given as
smoked cigarettes per day.
Fig. 1. Decrease of homocysteine serum levels during alcohol withdrawal.
Box plot showing the changes of homocysteine plasma levels during
withdrawal. Box represents 25–75 percentile and whiskers represent 5–95
percentile. Bar represents median and cross represents mean. Homocysteine
plasma levels decreased significantly during the course of withdrawal.
Statistical details are summarized in Results section.
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T = 2.30, P = 0.022), folate (B = −0.75, T = −5.47, P < 0.001)
and riboflavin (B = −0.06, T = −3.44, P = 0.001), but not by
thiamine, pyridoxine or cobalamin serum levels. Correlation
analysis revealed no significant association between folate
and riboflavin levels (r = 0.119, P = 0.121). To test which
factors influence the changes of HCY levels over time (Days
1, 7 and 11), we performed a general linear model computing
BAC and vitamin levels as covariates. We found a significant
interaction between HCY changes over time and BAC on ad-
mission (F = 4.80, P = 0.009), folate serum levels on admis-
sion (F = 7.02, P = 0.001) and riboflavin serum levels on
admission (F = 3.228, P = 0.042), but not with other tested
variables (thiamine, pyridoxine or cobalamin). Including the
interaction between folate and riboflavin and omitting thia-
mine, pyridoxine and cobalamin results did not relevantly
differ regarding the influence of thiamine, riboflavin and
BAC on changes of HCY over time without showing a sig-
nificant effect of the interaction (folate/riboflavin: F = 1.56, P
= 0.214).
Comparing the subgroups of patients with high (HCY
>15.35 μmol/l, n = 84) and low (HCY ≤15.36 μmol/l, n = 84)
HCY serum levels at admission, t-test for independent
samples revealed that the high-HCY group also showed sig-
nificantly elevated HCY levels on Day 7 (T = 6.4, P < 0.001)
and elevated HCY levels on Day 11 (T = 6.0, P < 0.0001) as
well as reduced folate (T = −6.3, P < 0.001), riboflavin (T =
−2.7, P = 0.008) and pyridoxine (T = −2.1, P = 0.039) serum
levels at admission.
Additionally, we performed the described linear regression
analysis separately for both genders. This analysis showed a
significant influence on HCY serum levels in male patients
for folate (B = −0.78, T = −5.16, P < 0.001) and riboflavin
(B = −0.05, T = −3.01, P = 0.003) but not for BAC, thiamine,
pyridoxine and cobalamin. In female patients, the analysis
showed a significant influence on HCY for folate (B = −0.74,
T = −2.61, P = 0.012) and BAC (B = 3.52, T = 2.27, P =
0.028), not for any of the other included variables.
Furthermore, we compared smoking and non-smoking
patients at the time of inclusion into the study. Using the pre-
viously described linear regression analysis, the results show
a significant influence on HCY levels at Day 1 for folate (B
= −0.67, T = −2.41, P = 0.22), thiamine (B = 0.07, T = 2.14,
P = 0.40) and riboflavine (B = −0.09, T = −2.25, P = 0.032) in
the group of non-smoking patients (n = 39) and a significant
finding for folate (B = −0.76, T = 0–4.54, P < 0.001), ribofla-
vine (B = −0.5, T = −2.5, P = 0.013) and BAC (B = 2.04, T =
2.33, P = 0.021) in the smokers’ group (n = 129)
DISCUSSION
The present investigation confirms previous observations that
reported elevated HCY levels in patients with alcohol depend-
ence undergoing detoxification treatment. As shown previ-
ously, on the time of admission the extent of the HCY serum
levels depends significantly on BAC (Bleich et al., 2000b,
2005). However, apart from BAC, serum levels of riboflavin
and folate also showed a significant influence on HCY serum
levels at admission (Day 1), at least in the male subgroup.
The same result was found when general linear model
analysis was performed, analyzing the effect of BAC and
B-vitamins on the changes of HCY during withdrawal.
Interestingly, cobalamin and pyridoxine showed no signifi-
cant influence on HCY. The same results were found when
comparing patients according to nicotine consumption and
gender. This result is in line with previous studies showing a
specific importance of folate and riboflavin supplementation
on HCY serum levels in healthy volunteers (Ganji and Kafai,
2004; Araki et al., 2006), which may also depend on the
MTHFR genotype (Chuang et al., 2006). Recently, riboflavin
has also been studied as dietary supplement during pregnancy
showing an effect on maternal HCY levels but not on orofa-
cial clefts in the offspring (Vujkovic et al., 2010). However,
riboflavin, which, to our knowledge, has not been studied in
the context of alcohol-associated hyperhomocysteinemia
before, showed a significant impact on HCY levels, which
did not depend on its interaction with folate. Riboflavin is a
precursor of various flavin coenzymes, particularly of FAD,
which is a coenzyme of MTHFR (Moat et al., 2003).
Substituted by FAD MTHFR catalyses 5,10-methylenetetrafo-
late to 5-methylenetetrafolate, which is of importance as a
donor of methyl groups for remethylation of HCY (Moat
et al., 2003). Accordingly, MTHFR activity is reduced in
ribloflavin-deficient rats (Bates and Fuller, 1986).
It is surprising and difficult to interpret that we found no
interaction between riboflavin and folate in our patient group.
In further studies, it may be interesting to include analysis of
FAD, which we did not perform in our study but which is the
active coenzyme in the folate-dependent MTHFR metabolism
(Hustad et al., 2002; Jacques et al., 2002).
However, the present work suffers from several limita-
tions: first, an influence of withdrawal medication with ben-
zodiazepines and possibly also with clomethiazole on HCY
levels cannot be ruled out and was recently stated in a clinic-
al study (Pompeia et al., 2009). The lack measurements of
vitamin serum level on Day 7 and 11 must also be consid-
ered a limitation. Furthermore, the lack of an association
between cobalamin and pyridoxine and HCY in the regres-
sion analysis is surprising. This may be explained at least
partially by the wide variations in both vitamin serum levels.
Overall, our results show that, apart from individual BAC,
folate and riboflavin plasma levels on admission contribute
to HCY elevation in alcohol-dependent patients. This effect
was not only shown at the beginning of in-patient treatment
but also regarding the decline of HCY during the withdrawal
period. Noteworthy, only a negligible number of patients suf-
fered from a definite B-vitamin deficiency. Thus, the present
findings support the hypothesis that a supplementation of
folate and riboflavin may be useful in alcohol-dependent
patients during active drinking as well as detoxification and
that currently used reference values for B-vitamins may need
to be adjusted for alcohol-dependent patients.
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